DV2-HBV-27: Observational Pregnancy Registry

UnknownOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 21, 2021

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Pregnant
Interventions
BIOLOGICAL

HEPLISAV-B

This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.

Trial Locations (1)

28401

PPD Registry Office, Recruiting Nationwide, Wilmington

All Listed Sponsors
collaborator

PPD, Part of Thermo Fisher Scientific

INDUSTRY

lead

Dynavax Technologies Corporation

INDUSTRY

NCT03664648 - DV2-HBV-27: Observational Pregnancy Registry | Biotech Hunter | Biotech Hunter